Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) and keeping the price target at $35.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors influencing Liquidia Technologies’ stock. A significant legal victory for Liquidia has been achieved as a judge ruled in favor of the company and the FDA, dismissing the ongoing lawsuit with United Therapeutics. This decision removes a major obstacle for Liquidia’s Yutrepia, allowing its path to approval to proceed without hindrance.
Furthermore, the ruling aligns with previous judicial decisions that support the FDA’s interpretation of its policies, which is favorable for Liquidia. With the path cleared for a potential approval date in May 2025, the outlook for Yutrepia’s market entry appears promising. These developments, along with the company’s current financial metrics, contribute to the Buy rating as they suggest a positive trajectory for Liquidia’s future performance.
In another report released on April 23, Scotiabank also maintained a Buy rating on the stock with a $34.00 price target.